Prelude Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.88M | Buy |
5,752
+4,916
| +588% | +$2.36M | 0.21% | 119 |
|
|
2026
Q1 | $411K | Sell |
836
-822
| -50% | -$446K | 0.03% | 587 |
|
|
2025
Q4 | $961K | Buy |
1,658
+1,102
| +198% | +$623K | 0.07% | 324 |
|
|
2025
Q3 | $270K | Sell |
556
-2
| -0.4% | -$931 | 0.02% | 780 |
|
|
2025
Q2 | $226K | Buy |
+558
| New | +$233K | 0.02% | 749 |
|
|
2024
Q4 | – | Sell |
-349
| Closed | -$216K | – | 1566 |
|
|
2024
Q3 | $216K | Sell |
349
-306
| -47% | -$181K | 0.01% | 1024 |
|
|
2024
Q2 | $362K | Buy |
655
+129
| +25% | +$73.9K | 0.03% | 700 |
|
|
2024
Q1 | $306K | Buy |
+526
| New | +$295K | 0.02% | 880 |
|
|
2023
Q4 | – | Sell |
-3,856
| Closed | -$1.95M | – | 1344 |
|
|
2023
Q3 | $1.95M | Buy |
3,856
+1,390
| +56% | +$741K | 0.13% | 197 |
|
|
2023
Q2 | $1.29M | Buy |
2,466
+2,034
| +471% | +$1.1M | 0.08% | 269 |
|
|
2023
Q1 | $249K | Sell |
432
-39
| -8% | -$22K | 0.01% | 743 |
|
|
2022
Q4 | $259K | Sell |
471
-707
| -60% | -$375K | 0.01% | 856 |
|
|
2022
Q3 | $597K | Buy |
1,178
+233
| +25% | +$130K | 0.02% | 586 |
|
|
2022
Q2 | $513K | Sell |
945
-3,047
| -76% | -$1.68M | 0.01% | 798 |
|
|
2022
Q1 | $2.36M | Buy |
+3,992
| New | +$2.29M | 0.07% | 289 |
|
|
2021
Q4 | – | Sell |
-2,058
| Closed | -$1.18M | – | 2247 |
|
|
2021
Q3 | $1.18M | Buy |
2,058
+699
| +51% | +$384K | 0.03% | 494 |
|
|
2021
Q2 | $686K | Buy |
+1,359
| New | +$641K | 0.02% | 797 |
|
|
2020
Q4 | – | Sell |
-479
| Closed | -$211K | – | 1991 |
|
|
2020
Q3 | $211K | Buy |
+479
| New | +$198K | 0.01% | 672 |
|
|
2019
Q3 | – | Sell |
-303
| Closed | -$89K | – | 2047 |
|
|
2019
Q2 | $89K | Buy |
+303
| New | +$83.5K | ﹤0.01% | 979 |
|
|
2019
Q1 | – | Sell |
-4,307
| Closed | -$1.07M | – | 2174 |
|
|
2018
Q4 | $964K | Buy |
+4,307
| New | +$1.01M | 0.06% | 326 |
|
|
2016
Q4 | – | Sell |
-3,107
| Closed | -$494K | – | 1775 |
|
|
2016
Q3 | $494K | Sell |
3,107
-214
| -6% | -$33K | 0.05% | 318 |
|
|
2016
Q2 | $491K | Buy |
3,321
+257
| +8% | +$37.9K | 0.07% | 288 |
|
|
2016
Q1 | $434K | Sell |
3,064
-2,678
| -47% | -$359K | 0.06% | 329 |
|
|
2015
Q4 | $815K | Buy |
5,742
+3,178
| +124% | +$424K | 0.13% | 188 |
|
|
2015
Q3 | $314K | Sell |
2,564
-4,848
| -65% | -$632K | 0.05% | 418 |
|
|
2015
Q2 | $962K | Buy |
7,412
+1,404
| +23% | +$183K | 0.13% | 184 |
|
|
2015
Q1 | $807K | Buy |
6,008
+698
| +13% | +$90K | 0.11% | 225 |
|
|
2014
Q4 | $665K | Buy |
5,310
+1,440
| +37% | +$175K | 0.1% | 235 |
|
|
2014
Q3 | $471K | Hold |
3,870
| – | – | 0.07% | 393 |
|
|
2014
Q2 | $457K | Buy |
3,870
+1,300
| +51% | +$153K | 0.06% | 414 |
|
|
2014
Q1 | $309K | Buy |
2,570
+1,870
| +267% | +$222K | 0.04% | 581 |
|
|
2013
Q4 | $78K | Buy |
+700
| New | +$69.6K | 0.01% | 955 |
|
|
2013
Q3 | – | Sell |
-600
| Closed | -$51K | – | 1833 |
|
|
2013
Q2 | $51K | Buy |
+600
| New | +$49.9K | 0.01% | 820 |
|
Other funds holding TMO
Prelude Capital Management's TMO Position: Q2 2026 in Review
Prelude Capital Management increased its Thermo Fisher Scientific (TMO) stake by 588% in Q2 2026, buying an estimated $2.36M and bringing the position to 5,752 shares worth $2.88M. The position accounts for 0.21% of the portfolio, ranked #119.
Prelude Capital Management first reported a position in TMO in Q2 2013 and has held it in 33 quarters since. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Prelude Capital Management held 5,752 shares of Thermo Fisher Scientific worth $2.88M as of Q2 2026.
- Prelude Capital Management bought 4,916 Thermo Fisher Scientific shares in Q2 2026, an estimated $2.36M.
- Thermo Fisher Scientific made up 0.21% of Prelude Capital Management's portfolio in Q2 2026, its #119 holding.
- Prelude Capital Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 33 quarters since.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.